Preclinical Pipeline


Adherex's preclinical portfolio includes back-up peptides and small chemical molecule successors to ADH-1; peptides and small molecules targeted to inhibiting the metastatic spread of some cancers; and, peptides that combine both angiolytic and anti-angiogenic properties.

Our preclinical portfolio is focused on the following three areas: